Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) rose 0% during mid-day trading on Friday . The stock traded as high as $1.30 and last traded at $1.18. Approximately 944,600 shares traded hands during trading, an increase of 50% from the average daily volume of 630,598 shares. The stock had previously closed at $1.18.

OREX has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. ValuEngine raised shares of Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

The company has a debt-to-equity ratio of -2.75, a current ratio of 2.00 and a quick ratio of 1.71. The firm has a market cap of $23.43, a price-to-earnings ratio of -0.12 and a beta of 1.96.

A hedge fund recently raised its stake in Orexigen Therapeutics stock. Wells Fargo & Company MN increased its position in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 2.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,638 shares of the biopharmaceutical company’s stock after buying an additional 1,100 shares during the period. Wells Fargo & Company MN owned 0.30% of Orexigen Therapeutics worth $132,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 29.86% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Orexigen Therapeutics (OREX) Stock Price Up 0%” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at

About Orexigen Therapeutics

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with's FREE daily email newsletter.